All Features

Use the tool below to view all available Global Neurology Academy Series

Managing NF1 PN with this First and Only FDA-Approved Treatment Option
Managing NF1 PN with this First and Only FDA-Approved Treatment Option
NeuroFrontiers
Managing NF1 PN with this First and Only FDA-Approved Treatment Option
- Sandy Millman
- Pinki Prasad, MD
The Gene Messenger: Advancing Neurological Gene Therapy
The Gene Messenger: Advancing Neurological Gene Therapy
Medical Industry Feature
The Gene Messenger: Advancing Neurological Gene Therapy
- Michael Kaplitt, MD, PhD
The Network Effect: Analyzing Brain Structures to Treat Depression
The Network Effect: Analyzing Brain Structures to Treat Depression
Medical Industry Feature
The Network Effect: Analyzing Brain Structures to Treat Depression
- Conor Liston, MD, PhD
Disparities in DMT Access: Women with MS Are Less Likely to Receive Treatment
Disparities in DMT Access: Women with MS Are Less Likely to Receive Treatment
NeuroFrontiers
Disparities in DMT Access: Women with MS Are Less Likely to Receive Treatment
- Andrew Wilner, MD, FACP, FAAN
- Victoria Leavitt, PhD
Shedding Light on the Brain After COVID-19: Assessing the Spectrum of Neurological Risk
Shedding Light on the Brain After COVID-19: Assessing the Spectrum of Neurological Risk
NeuroFrontiers
Shedding Light on the Brain After COVID-19: Assessing the Spectrum of Neurological Risk
- Andrew Wilner, MD, FACP, FAAN
- Jennifer A. Frontera, MD

Contact us